Gut incretin hormones such as glucagon-like peptide 1 (GLP-1) and gastric inhibitory polypeptide (GIP) are classically defined as potentiators of GSIS, and defects in their signaling pathways are known to contribute to the inappropriate glucose control of T2D [15]. Here, GIP is linked to type 2 diabetes mellitus.